On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million people, or 9.4% of the total population, have completed a vaccination series.1
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Athalia Christie, MIA, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333 (firstname.lastname@example.org).
Published Online: March 10, 2021. doi:10.1001/jama.2021.4367
Conflict of Interest Disclosures: None reported.
Additional Contributions: We wish to acknowledge Heidi M. Soeters, PhD (CDC).
You currently have no searches saved.
You currently have no courses saved.